Physician profile
Salar Hakham
NPI 1386960854
$225,228.95
in general payments reported to CMS, 2019-2025
8 companies · $78K in 2025
The $78K reported for 2025 was more than what 98% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $267 · 2021: $442 · 2022: $12K · 2023: $71K · 2024: $63K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $210K · Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $209,916.67 |
| Food and Beverage | $2,050.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $223,429.31 | 2019-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac, Bioflo |
| Abbott Laboratories | $621.85 | 2020-2021 | |
| Boston Scientific Corporation | $472.79 | 2019-2024 | Opticross 35, Innova Vascular |
| Bard Peripheral Vascular, INC. | $250.00 | 2023-2025 | Rotarexs 6 F X 135 Cm, Venclose Maven Catheter, Lifestent Solo Vascular Stent |
| Philips North America LLC | $239.51 | 2019-2023 | |
| Medtronic, INC. | $169.64 | 2024 | Intellis Adaptivestim |
| Medline Industries Lp | $25.00 | 2025 | |
| Dova Pharmaceuticals | $20.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salar Hakham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.